Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Osteoporosis Reports
Published in: Current Osteoporosis Reports 3/2015

01-06-2015 | Kidney and Bone (SM Moe and IB Salusky, Section Editors)

Sclerostin and CKD-MBD

Author: Susan C. Schiavi

Published in: Current Osteoporosis Reports | Issue 3/2015

Login to get access

Abstract

Declining kidney function is associated with sequential systemic changes in mineral homeostasis leading to pathologic alterations in the cardiovascular system and the skeleton. One of the earliest changes in response to renal injury is the increased osteocyte production of secreted factors including the anti-anabolic protein, sclerostin. Elevated sclerostin is associated with reduced Wnt/β-catenin signaling in bone and decreased osteoblast differentiation/activity. Agents that directly or indirectly inhibit β-catenin signaling have differential skeletal effects suggesting additional mechanisms contribute to the diversity of renal osteodystrophies. Similarly, Wnt/β-catenin activation in smooth muscle cells contributes to cardiovascular calcification yet emerging data suggests that this pathway may also be protective when elevated in neighboring tissues. The ongoing epidemiology studies examining the relationship between circulating sclerostin and cardiovascular disease, particularly those that investigate stage specific and/or patient sub-populations, will be useful in understanding the overall contributions of this pathway, its antagonist sclerostin, and the progression of CKD-MBD.
Literature
1.
Moe S, Drueke T, Cunningham J, et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int. 2006;69:1945–53.CrossRefPubMed
2.
Moe SM. Definition and classification of renal osteodystrophy and chronic kidney disease-mineral bone disorder (CKD-MBD). In: Olgaard K, Salusky IB, Silver J, editors. The spectrum of mineral and bone disorders in chronic kidney disease. New York: Oxford University; 2010. p. 1–14.CrossRef
3.•
Lu K-C, Wu C-C, Yen JF. Vascular calcification and renal bone disorders. Sci World J. 2014;637065:1–20. A comprehensive review summarizing the link between poor bone health and cardiovascular disease in CKD.
4.
5.
Hu MC, Shiizaki K, Kuro-o M, Moe OW. Fibroblast growth factor 23 and Klotho: physiology and pathophysiology of an endocrine network of mineral metabolism. Annu Rev Physiol. 2013;75:503–33.CrossRefPubMedCentralPubMed
6.
Quarles D. A systems biology preview of the relationships between mineral and metabolic complications in chronic kidney disease. Semin Nephrol. 2013;33:130–42.CrossRefPubMed
7.
Krisnan V, Bryant HU, MacDougald OA. Regulation of bone mass by Wnt signaling. J Clin Invest. 2006;116:1202–9.CrossRef
8.••
Baron R, Kneissel M. WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nature Med. 2013;19:179–92. Outstanding review article describing evidence based mechanistic understanding of canonical Wnt/β-catenin signaling and its role in bone biology.CrossRefPubMed
9.
Modder UI, Hoey KA, Amin S, et al. Relation of age, gender, and bone mass to circulating sclerostin levels in women and men. J Bone Miner Res. 2011;26:373–9.CrossRefPubMedCentralPubMed
10.
Li X, Ominsky MS, Warminghton KS, et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of post-menopausal osteoporosis. J Bone Miner Res. 2009;24:578–88.CrossRefPubMed
11.
Ominsky MS, Vlasseros F, Jolette J, et al. Two doses of anti-sclerostin antibody in cynomologus monkeys increases bone formation, bone mieral density, and bone strength. J Bone Miner Res. 2010;25:948–59.CrossRefPubMed
12.
Padhi D, Jang G, Stouch B, et al. Single dose placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res. 2011;26:19–26.CrossRefPubMed
13.
14.
Poole KE, Reeve J. Parathyroid hormone: a double-edged sword for bone metabolism. Curr Opin Pharmacol. 2005;5:612–7.CrossRefPubMed
15.
Kramer I, Kellar H, Leupin O, Kniessel M. Does osteocytic SOST suppression mediate PTH anabolism? Trends in Endocr Metab. 2010;21:237–44.CrossRef
16.
17.
Brandenburg VM, Floege J. Adynamic bone disease—bone and beyond. Nephrol Dial Transpl. 2008;3:135–47.
18.
Rocha LA, Higa A, Barreto FC, et al. Variant of adynamic bone disease in hemodialysis patients: fact or fiction? Am J Kidney Dis. 2006;48:430–6.CrossRefPubMed
19.
Lund RJ, Davies MR, Matthew S, Hruska K. New discoveries in the pathogenesis of renal osteodystrophy. J Bone Miner Res. 2006;24:169–71.CrossRef
20.••
Sabbagh Y, Graciolli FG, O’Brien S, et al. Repression of osteocyte Wnt/β-catenin signaling is an early event in the progression of renal osteodystrophy. J Bone Min Res. 2012;27:1757–72. First mechanistic evidence that repression of Wnt/β-catenin signaling is associated with CKD in mouse bones and clinical biopsies.CrossRef
21.
Kramer I, Halleux C, Keller H, et al. Osteocyte Wnt/beta-catenin signaling is required for normal bone homeostasis. Mol Cell Biol. 2010;30:3072–85.CrossRef
22.
Wijenayaka AR, Kogawa M, Lim HP. Sclerostin stimulates osteocyte support of osteoclast activity by a RANKL-dependent pathway. PLoS One. 2011;10:e25900.CrossRef
23.
Moyses R. Osteocyte regulation in renal osteodystrophy. Presented Am Soc Nephrology, Philadelphia, PA, 2014.
24.
Bellido T, Ali AA, Gubrij I, et al. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology. 2005;146:4577–83.CrossRefPubMed
25.
26.••
Moe SM, Chen NX, Newman CL, et al. Anti-sclerostin antibody treatment in a rat model of progressive renal osteodystrophy. J Bone Miner Res. 2014. doi:10.​1002/​jbmr.​2372. Describes preclinical effects of anti-sclerostin antibody on low and not high bone turnover.PubMedCentral
27.
Fang Y, Ginsberg C, Sugatani T, et al. Early chronic kidney disease-mineral bone disorder stimulates vascular calcification. Kidney Intern. 2013;85:142–50.CrossRef
28.•
Fang Y, Ginsberg C, Seifert M. CKD-induced wingless/integration1 inhibitors and phosphorus cause the CKD-MBD. J Am Soc Nephrol. 2014;25:1760–73. Study provides evidence that injured kidneys may release Wnt antagonists into circulation and that antagonism with neutralizing antibodies can treat low bone disease and vascular calcification. Evidence that aberrant Wnt signaling in endocrine cells is associated with vascular calcification.CrossRefPubMed
29.••
Liu S, Song W, Boulanger JH, et al. Role of TGF-b in a mouse model of high turnover renal osteodystrophy. J Bone Min Res. 2014;29:1141–57. Important study suggesting a role for TGFβ involvement in early pathogenesis of high turnover bone disease.CrossRef
30.
Janssens K, ten Dijke P, Janssens S, Van Hul W. Transforming growth factor β1 to the bone. Endocr Rev. 2005;26:743–74.CrossRefPubMed
31.
Tang Y, Wu X, Lei W, et al. TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat Med. 2009;15:757–65.CrossRefPubMedCentralPubMed
32.
Alliston T, Choy L, Ducy P, Karsenty G, Derynck R. TGF-beta-induced repression of CBFA1 by Smad3 decreases cbfa1 and osteocalcin expression and inhibits osteoblast differentiation. EMBO J. 2001;20:2254–72.CrossRefPubMedCentralPubMed
33.
Grafe I, Yang T, Alexander S, et al. Excessive transforming growth factor-β signaling is a common mechanism in osteogenesis imperfecta. Nat Med. 2014;20:670–5.CrossRefPubMedCentralPubMed
34.
Zhen G, Wen C, Jia X, Li Y, et al. Inhibition of TGF-β signaling in mesenchymal stem cells of subchondral bone attenuates osteoarthritis. Nat Med. 2013;19:704–12.CrossRefPubMedCentralPubMed
35.
Gu X, Wang XF. Signaling cross-talk between TGF-β/BMP and other pathways. Cell Res. 2009;19:71–88.CrossRef
36.
Qui T, Wu X, Zhang F, et al. TGF-β type II receptor phosphorylates PTH receptor to integrate bone remodeling signaling. Nature Cell Biol. 2010;12:224–34.
37.•
Nguyen J, Tang SY, Nguyen D, Alliston T. Load regulates bone formation and sclerostin expression through a TGFβ-dependent mechanism. PLoS One. 2013;8:1547–53. Provides mechanistic link between TGFβ and sclerostin regulation.
38.•
Cejka D, Herberth J, Branscum AJ, et al. Sclerostin and Dickkopf-1 in renal osteodystrophy. Clin J Am Soc Nephrol. 2011;6:877–82. First report of elevated sclerostin levels in CKD demonstrating relationship with bone formation rates.CrossRefPubMedCentralPubMed
39.•
Pelletier S, Dubourg L, Carlier MC, et al. The relation between renal function and serum sclerostin in adult patients with CKD. Clin J Am Soc Nephrol. 2012;8:819–23. Provides assessment of sclerostin serum expression across all stages of CKD progression.
40.
Viaene L, Behets GJ, Claes K, et al. Sclerostin: another bone-related protein related to all-cause mortality in haemodialysis? Dephrol Dial Transplant. 2013;28:3024–30.CrossRef
41.•
Malluche HH, Davenport DL, Cantor T, Monier-Faugere M-C. Bone mineral density and serum biochemical predictors of bone loss in patients with CKD on dialysis. Clin J Am Soc Nephrol. 2014;9:1254–62. Prospective study examining the relationship over time between serum sclerostin and bone mass.
42.•
Drechsler C, Evenepoel P, Vervloet MG, et al. High levels of circulating sclerostin are associated with better cardiovascular survival in incident dialysis patients: results from the NECOSAD study. Nephrol Dial Transplant. 2014;0:1–6. Largest prospective study to date examining relationship between serum sclerostin and cardiovascular events.
43.
Thambiah S, Roplekar R, Manghat P, et al. 2012; Circulating sclerostin and dickkopf1 (DKK1) in predialysis chronic kidney disease (CKD): relationship with bone density and arterial stiffness. Calcif Tissue Int. 2012;90:473–80.CrossRefPubMed
44.
Claes KJ, Viaene L, Heye S, et al. Sclerostin: another vascular calcification inhibitor? J Clin Endocrin Metab. 2013;98:3221–8.CrossRef
45.
De Oliveira RB, Graciolli FG, dos Reis LM, et al. Disturbances of Wnt/β-catenin pathway and energy metabolism in early CKD: effect of phosphate binders. Nephrol Dial Transplant. 2013;28:2510–7.CrossRefPubMed
46.
Isakova T Circulating sclerostin as a marker of bone health and disease. Presented at the American Society of Nephrology, Philadelphia, PA, 2014.
47.
McNulty M, Singh RJ, Li X. et al. Determination of serum and plasma sclerostin concentrations by enzyme-linked immunoassays. J Clin Endocrinol Metab. 2011;96:E11159-62.
48.
Costa AG, Cremers S, Dworakowski E, et al. Comparison of two commercially available ELISAs for circulating sclerostin. Osteoporos Int. 2014;25:1547–54.CrossRefPubMed
49.
Bonani M, Rodriguez D, Fehr T, et al. Sclerostin blood levels before and after kidney transplantation. Kidney Blood Press Res. 2014;39:230–9.CrossRefPubMed
50.
51.
Ardawi MS, Rouzi AA, Al-Sibiani SA. High serum sclerostin predicts the occurrence of osteoporotic fractures in postmenopausal women: the Center of Excellence for Osteoporosis Research Study. J Bone Miner Res. 2012;27:2592–602.CrossRefPubMed
52.
Ardawi MS1, Akhbar DH, Alshaikh A, et al., Increased serum sclerostin and decreased serum IGF-1 are associated with vertebral fractures among postmenopausal women with type-2 diabetes. Bone. 2013;56:355–62.
53.
Yamamoto M, Yamauchi M, Sugimoto T. Elevated sclerostin levels are associated with vertebral fractures in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2013;98:4030–7.CrossRefPubMed
54.
Steitz SA, Speer MY, Curinga G, et al. Smooth muscle cell phenotypic transition associated with calcification. Circ Res. 2001;89:1147–54.CrossRefPubMed
55.
Shao JS, Cheng SL, Pingsterhaus JM, et al. Msx2 promotes cardiovascular calcification by activating paracrine Wnt signals. J Clin Invest. 2005;115:1210–20.CrossRefPubMedCentralPubMed
Metadata
Title
Sclerostin and CKD-MBD
Author
Susan C. Schiavi
Publication date
01-06-2015
Publisher
Springer US
Published in
Current Osteoporosis Reports / Issue 3/2015
Print ISSN: 1544-1873
Electronic ISSN: 1544-2241
DOI
https://doi.org/10.1007/s11914-015-0263-2

Other articles of this Issue 3/2015

Current Osteoporosis Reports 3/2015 Go to the issue

Kidney and Bone (SM Moe and IB Salusky, Section Editors)

Bone is Not Alone: the Effects of Skeletal Muscle Dysfunction in Chronic Kidney Disease

Kidney and Bone (SM Moe and IB Salusky, Section Editors)

Bone Imaging and Fracture Risk Assessment in Kidney Disease

Rare Bone Disease (CB Langman and E Shore, Section Editors)

GNAS Spectrum of Disorders

Bone and Diabetes (AV Schwartz and P Vestergaard, Section Editors)

An Overview of the Metabolic Functions of Osteocalcin

Bone and Diabetes (AV Schwartz and P Vestergaard, Section Editors)

Bone Cells and Bone Turnover in Diabetes Mellitus

Osteoporosis and Cancer (P Clezardin and G van der Pluijm, Section Editors)

Chemotherapy- and Irradiation-Induced Bone Loss in Adults with Solid Tumors